(Q73850404)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837659%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Pharmacodynamic aspects of sustained release preparations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837659%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

Hoffman A

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837659%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 September 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837659%20AND%20SRC:MED&resulttype=core&format=json

Advanced Drug Delivery Reviews

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837659%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837659%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837659%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

185-199

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837659%20AND%20SRC:MED&resulttype=core&format=json

Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Influence of drug formulation on drug concentration-effect relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Bioavailability, clinical effectiveness, and the public interest

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Kinetics of pharmacologic response I. Proposed relationships between response and drug concentration in the intact animal and man

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: pharmacodynamic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Pharmacodynamics of intravenous ranitidine after bolus and continuous infusion in patients with healed duodenal ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Pharmacodynamic and pharmacokinetic rationales for the development of an oral controlled-release amoxicillin dosage form

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Continuous infusion of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Novel oral drug formulations. Their potential in modulating adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Integrated pharmacokinetic-dynamic modeling of drugs acting on the CNS.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Effects of low dose transdermal scopolamine on heart rate variability in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Cyclosporine affects central nervous system opioid activity via direct and indirect means

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Histamine-induced modulation of nociceptive responses

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Relationship between plasma prazosin concentration and alpha-antagonism in humans: comparison of conventional and rate-controlled (Oros) formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

The influence of food intake on the effect of two controlled release formulations of furosemide.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Continuous infusion of loop diuretics in the critically ill: a review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Delayed tolerance to furosemide diuresis. Influence of angiotensin converting enzyme inhibition by lisinopril

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Control of pulsatile insulin secretion in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Pharmacodynamics of gonadotropin-releasing hormone. 1. Effects of gonadotropin-releasing hormone pulse contour on pituitary luteinizing hormone secretion in vivo in sheep

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

The insulin receptor concept and its relation to the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Hepatic Arterial Infusion (HAI) chemotherapy proves to be advantageous in the treatment of experimental liver tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Pharmacodynamic aspects of drug administration. Tolerance development

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Role of pharmacokinetics in the outcome of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Evaluation of the efficiency of targeting of antitumor drugs: simulation analysis based on pharmacokinetic/pharmacodynamic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Chronopharmacologic considerations when treating the patient with hypertension: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Circadian-system alterations during cancer processes: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

Pharmacokinetic considerations of new insulin formulations and routes of administration

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2898%2900027-1

7 January 2021

10.1016/S0169-409X(98)00027-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10837659%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference